Search results for "Phase 3 clinical trial"

550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair

550 Days in Limbo: Groups Demand 100-Day Fast-Track Insurance Coverage for Breakthrough PAH Drug Winrevair

With national health insurance coverage for the new pulmonary arterial hypertension treatment Winrevair (active ingredient: sotatercept) remaining in...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27

Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's Ministry of Food and Drug Safety...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial

VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial

Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use

HK inno.N's K-CAB Secures Sixth Indication to Prevent Ulcers from Long-Term NSAID Use

HK inno.N’s gastroesophageal reflux disease drug K-CAB has expanded its approved uses to include the prevention of...
Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia

OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C...
Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Forget Wegovy and Mounjaro: How Hanmi’s 'EPPE' Is Redefining Obesity Care

Hanmi Pharmaceutical has officially named its in-development obesity treatment "EPPE.
South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

South Korea Ranks in GSK’s Global Top 10 for Clinical Research, with Over 70 Trials Underway

"South Korea is among the top 10 markets in GSK’s global clinical research. More than 70 clinical programs are...
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short

Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven

Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition

GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition

A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
Languages

ENGLISH

English (US)

ASIAN

Монгол日本語Tiếng ViệtBahasa Indonesia中文 (简体, 中国大陆)

EUROPEAN

РусскийEspañol (España)Français (France)

MIDDLE_EAST_AFRICA

العربية